113 related articles for article (PubMed ID: 27600007)
1. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
Huang J; Zhao X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 41(8):809-14. PubMed ID: 27600007
[TBL] [Abstract][Full Text] [Related]
2. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
[TBL] [Abstract][Full Text] [Related]
4. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
[TBL] [Abstract][Full Text] [Related]
5. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.
Xia L; Qian W; Yang M; Li Q; Liu F; Xie Y
Onco Targets Ther; 2015; 8():2485-92. PubMed ID: 26392775
[TBL] [Abstract][Full Text] [Related]
7. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.
Ganta RR; Nasaka S; Linga VG; Gundeti S; Maddali LS; Digumarti RR
Indian J Med Paediatr Oncol; 2017; 38(3):282-286. PubMed ID: 29200674
[TBL] [Abstract][Full Text] [Related]
10. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
[TBL] [Abstract][Full Text] [Related]
11. [Values of Different Prognostical Score Systems in Evaluation of Clinical Efficacy for Patients with Newly Diagnosed Chronic Myeloid Leukemia].
Wang PP; Zhang PP; Zhang J; Xi YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):723-728. PubMed ID: 31204922
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers.
Sinha SK; Sinha S; Mandal PK; Bhattacharyya NK; Pandey A; Gupta P
Indian J Pathol Microbiol; 2013; 56(3):216-20. PubMed ID: 24152497
[TBL] [Abstract][Full Text] [Related]
13. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.
Yamamoto E; Fujisawa S; Hagihara M; Tanaka M; Fujimaki K; Kishimoto K; Hashimoto C; Itabashi M; Ishibashi D; Nakajima Y; Tachibana T; Kawasaki R; Kuwabara H; Koharazawa H; Yamazaki E; Tomita N; Sakai R; Fujita H; Kanamori H; Ishigatsubo Y
Cancer Sci; 2014 Jan; 105(1):105-9. PubMed ID: 24450386
[TBL] [Abstract][Full Text] [Related]
14. Risk Stratification of Chronic Myeloid Leukemia According to Different Prognostic Scores.
Aijaz J; Junaid N; Asif Naveed M; Maab R
Cureus; 2020 Mar; 12(3):e7342. PubMed ID: 32313783
[TBL] [Abstract][Full Text] [Related]
15. Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.
Yang X; Bai Y; Shi M; Zhang W; Niu J; Wu C; Zhang L; Xu Z; Liu X; Chen Y; Sun K
Cancer Manag Res; 2020; 12():1293-1301. PubMed ID: 32110103
[TBL] [Abstract][Full Text] [Related]
16. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
Gurrea Salas D; Glauche I; Tauer JT; Thiede C; Suttorp M
Ann Hematol; 2015 Aug; 94(8):1363-71. PubMed ID: 25894600
[TBL] [Abstract][Full Text] [Related]
17. Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.
Ganguly S; Lakshmaiah KC; Jacob LA; Babu S; Dasappa L; Govind Babu KS
Indian J Hematol Blood Transfus; 2017 Mar; 33(1):82-86. PubMed ID: 28194061
[TBL] [Abstract][Full Text] [Related]
18. The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience.
Dybko J; Jaźwiec B; Haus O; Urbaniak-Kujda D; Kapelko-Słowik K; Wróbel T; Lonc T; Sawicki M; Mędraś E; Kaczmar-Dybko A; Kuliczkowski K
Dis Markers; 2016; 2016():7531472. PubMed ID: 27818567
[TBL] [Abstract][Full Text] [Related]
19. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Med Oncol; 2015 Aug; 32(8):213. PubMed ID: 26143137
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
